AbCellera Biologics (ABCL) Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Does the media prefer CRSP or ABCL?

In the previous week, CRISPR Therapeutics had 29 more articles in the media than AbCellera Biologics. MarketBeat recorded 45 mentions for CRISPR Therapeutics and 16 mentions for AbCellera Biologics. CRISPR Therapeutics' average media sentiment score of 0.68 beat AbCellera Biologics' score of 0.30 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	7 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is CRSP or ABCL more profitable?

AbCellera Biologics has a net margin of -511.88% compared to CRISPR Therapeutics' net margin of -1,229.43%. AbCellera Biologics' return on equity of -16.17% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,229.43%	-20.05%	-17.09%
AbCellera Biologics	-511.88%	-16.17%	-12.24%

Which has stronger earnings and valuation, CRSP or ABCL?

AbCellera Biologics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$35M	150.37	-$366.25M	-$5.43	-10.66
AbCellera Biologics	$32.88M	41.59	-$162.86M	-$0.55	-8.32

Do analysts rate CRSP or ABCL?

CRISPR Therapeutics presently has a consensus price target of $71.60, suggesting a potential upside of 23.73%. AbCellera Biologics has a consensus price target of $8.00, suggesting a potential upside of 74.83%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, CRSP or ABCL?

CRISPR Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in CRSP or ABCL?

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

AbCellera Biologics beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.